Trial record 4 of 339 for:    "Charcot-Marie-Tooth disease"

Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Memorial Medical Center
ClinicalTrials.gov Identifier:
NCT00541164
First received: October 9, 2007
Last updated: July 11, 2013
Last verified: June 2010
  Purpose

The object of this research is to test the effectiveness of Coenzyme Q10 (CoQ10) on symptoms of weakness, fatigue, and pain in persons with Charcot-Marie-Tooth disease (CMT).In this study we also intend to examine the impact of daily supplementation on overall quality of life.We are also interested in identifying any differences in serum ratios of CoQ10 in the oxidized and reduced forms.


Condition Intervention Phase
Charcot Marie Tooth Disease
Drug: Coenzyme Q10
Dietary Supplement: Coenzyme Q10
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Effects of Coenzyme Q10 (CoQ10) on Subjects With Charcot-Marie-Tooth Disease (CMT):A Double Blind, Randomized, Controlled Trial With an Open Label Follow-up Study

Resource links provided by NLM:


Further study details as provided by Memorial Medical Center:

Primary Outcome Measures:
  • Changes in weakness, fatigue and pain in persons with Charcot-Marie-Tooth disease after supplementation with 600 mgs a day of Coenzyme Q10. [ Time Frame: 60 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Improvements in quality of life in subjects with CMT before and after CoQ10 supplementation. [ Time Frame: 60 weeks ] [ Designated as safety issue: No ]
  • Measure blood serum levels of the oxidized and reduced forms of CoQ10. [ Time Frame: 60 weeks ] [ Designated as safety issue: No ]
  • Measure liver function tests [ Time Frame: visits 1, 6, 12 ] [ Designated as safety issue: Yes ]

Enrollment: 23
Study Start Date: September 2007
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
300 mg CoQ10 chewable wafer twice a day
Drug: Coenzyme Q10
300 mg CoQ10 twice a day for 48 weeks
Other Names:
  • CoQ10
  • Ubiquinone
Placebo Comparator: 2
Chewable placebo wafer twice a day for 24 weeks with crossover to 300mg CoQ10 twice a day for weeks 24-48.
Dietary Supplement: Coenzyme Q10
300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
Other Names:
  • CoQ10
  • Ubiquinone

Detailed Description:

CoQ10 is an integral part of the electron transport chain in the mitochondria, or the energy production centers of cells. Within recent years, there has been expanding interest in the potential benefits of CoQ10 supplementation on a variety of neuromuscular diseases, some of which involve mitochondrial dysfunction, such as CMT. Daily supplementation may have cytoprotective and neuroprotective properties, which may improve symptoms of weakness, fatigue, and pain, as well as increase quality of life (QOL) among persons with CMT.

With regards to within group comparisons we hypothesize that daily supplementation of CoQ10 taken as a 300 milligram wafer twice a day for 3 months will produce a statistically significant reduction in weakness, fatigue, and pain, along with a significant improvement in QOL as indicated from scores in both standardized physiological and scale measures.

The addition of serum level analysis will help to contextualize clinical results. We hypothesize the ratios of the oxidized and reduced forms of CoQ10 will be modified upon supplementation.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have a diagnosis of CMT, confirmed by review of medical records by the study physician
  • Subjects can be of either gender
  • Subjects must be between the ages of 18 and 75
  • Subjects must be able to complete all assessments at the designated time intervals
  • Subjects must review and sign the informed consent statement according to Conemaugh Memorial Medical Center's (CMMC) Institutional Review Board (IRB) guidelines
  • Subjects must receive approval from their primary care physician (PCP) to enroll in the study
  • Regarding weakness, fatigue, and pain, subjects must experience at least two of the three symptoms on most days over the past month
  • Regarding weakness, fatigue, and pain, subjects must report experiencing maximum levels of >/= 3.0 centimeters (cm) on the 10 cm visual analog scale (VAS) for any two of the three symptoms over the past month
  • Female subjects must be willing to practice stable birth control during involvement in the study
  • Subjects must agree to be randomized

Exclusion Criteria:

  • Subjects having another general medical condition, which might confound the assessment of weakness, fatigue, and pain due to CMT
  • Subjects taking warfarin or Coumadin
  • Subjects who are pregnant, verified by a urine pregnancy test*
  • Subjects having a cognitive impairment scoring < 20 on the Mini-Mental State Exam
  • Subjects who are currently using CoQ10 supplementation or have used it in the past 6 months
  • Subjects with a history of chronic liver disease or other condition causing malabsorption
  • Drug intake that could modify lipid absorption (such as statins)
  • Subjects who consume >3 alcoholic drinks per day on more than one occasion per month
  • Subjects with abnormal liver function tests as defined through a Hepatic -Function Panel or a Liver Function Panel

    • Women of childbearing age who have had at least one menstrual cycle within the past 12 months and who have not undergone a sterilization procedure will undergo a urine pregnancy test at visits 1-10 regardless of group assignment in order to maintain the single blind. The urine samples will be processed at CMMC's lab
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00541164

Locations
United States, Pennsylvania
John P Murtha Neuroscience and Pain Institute
Johnstown, Pennsylvania, United States, 15904
Sponsors and Collaborators
Memorial Medical Center
Investigators
Principal Investigator: Sharon Plank, MD John P. Murtha Neuroscience and Pain Institute
  More Information

Publications:
Responsible Party: Memorial Medical Center
ClinicalTrials.gov Identifier: NCT00541164     History of Changes
Other Study ID Numbers: 05-19
Study First Received: October 9, 2007
Last Updated: July 11, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Memorial Medical Center:
CMT
Charcot-Marie Tooth
CoQ10
Coenzyme Q10

Additional relevant MeSH terms:
Charcot-Marie-Tooth Disease
Nerve Compression Syndromes
Hereditary Sensory and Motor Neuropathy
Tooth Diseases
Nervous System Malformations
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Polyneuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Congenital Abnormalities
Genetic Diseases, Inborn
Stomatognathic Diseases
Coenzyme Q10
Ubiquinone
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Vitamins

ClinicalTrials.gov processed this record on April 17, 2014